The safety and efficacy of palbociclib in older patients with advanced breast cancer in a real-world setting

Abstract

Aims: Palbociclib has been approved in combination with endocrine therapy (ET) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), regardless of age. Even though ABC is one of the most prevalent cancers in older patients, very few patients ≥ 65 years old were included in pivotal trials. Therefore, the current study evaluated the safety and efficacy of palbociclib in “real-world” routine treatment of unselected older patients with HR+/HER2- ABC.

Methods: Data were collected on patients > 70 years old who were treated with palbociclib plus ET for HR+/HER2- ABC in our institution. We analyzed safety data (CTCAE v4.0 criteria) and outcomes, such as progression-free survival (PFS) and overall survival (OS), as well as any associations between main geriatric characteristics and our results. Furthermore, we assessed safety at a national level by analyzing all palbociclib-related adverse events (AEs) reported in the French Pharmacovigilance Database (FPVD) during the same period.

Results: From February 2016 to July 2019, 52 patients were identified with a median age of 80.9 years, of whom 88% presented an AE. The most common grade 3-4 AE was neutropenia (64%). Median PFS and OS were nine months and not reached, respectively. The FPVD reports 227 cases of palbociclib-related AEs, with older and younger patients sharing similar characteristics.

Conclusion: Palbociclib is well tolerated in older patients with efficacy comparable to that in younger patients. However, the addition of palbociclib to ET should be evaluated individually in this older and frailer subgroup.

Keywords

Advanced breast cancer, palbociclib, older patients, tolerance / efficacy, pharmacovigilance

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.CA Cancer J Clin2021;71:209-49

[2] Mela A,Drop B.Overview and analysis of the cost of drug programs in poland: public payer expenditures and coverage of cancer and non-neoplastic diseases related drug therapies from 2015-2018 Years.Front Pharmacol2020;11:1123 PMCID:PMC7456857

[3] Purrahman D,Saki N,Kurkowska-Jastrzębska I.Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer.Cytokine2022;151:155803

[4] Yersal O.Biological subtypes of breast cancer: Prognostic and therapeutic implications.World J Clin Oncol2014;5:412-24 PMCID:PMC4127612

[5] Nakagawa T,Ogawa A.Bone marrow carcinomatosis in a stage IV breast cancer patient treated by letrozole as first-line endocrine therapy.Case Rep Oncol2022;15:436-41 PMCID:PMC9149407

[6] Feng Y,Huang S.Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.Genes Dis2018;5:77-106 PMCID:PMC6147049

[7] Bergen ES,Berghoff AS.Prognostic impact of breast cancer subtypes in elderly patients.Breast Cancer Res Treat2016;157:91-9 PMCID:PMC4866984

[8] Kartal M,Canda T.Diagnosis, treatment characteristics, and survival of women with breast cancer aged 65 and above: a hospital-based retrospective study.BMC Womens Health2013;13:34 PMCID:PMC3765714

[9] Baban CK,Geraghty J.Change of paradigm in treating elderly with breast cancer: are we undertreating elderly patients?.Ir J Med Sci2019;188:379-88

[10] Fry DW,Keller PR.Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.Mol Cancer Ther2004;3:1427-38

[11] Finn RS,Conklin D.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.Breast Cancer Res2009;11:R77 PMCID:PMC2790859

[12] Finn RS,Lang I.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.Lancet Oncol2015;16:25-35

[13] Finn RS,Rugo HS.Palbociclib and letrozole in advanced breast cancer.N Engl J Med2016;375:1925-36

[14] Turner NC,André F.Palbociclib in hormone-receptor-positive advanced breast cancer.N Engl J Med2015;373:209-19

[15] Cristofanilli M,Bondarenko I.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Lancet Oncol2016;17:425-39

[16] Turner NC,Ro J.Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med2018;379:1926-36

[17] Ibrance - EMEA/H/C/003853 - IB/0032.

[18] Singh H,Smith C.FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.JCO2017;35:10009

[19] Rugo HS,Finn RS.Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.Eur J Cancer2018;101:123-33

[20] Howie LJ,Bloomquist E.Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis.J Clin Oncol2019;37:3475-83

[21] Soubeyran P,Goyard J.Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study.PLoS One2014;9:e115060 PMCID:PMC4263738

[22] Katz S,Moskowitz RW,Jaffe MW.Studies of illness in the aged the index of adl: a standardized measure of biological and psychosocial function.JAMA1963;185:914-9

[23] Lawton MP.Assessment of older people: self-maintaining and instrumental activities of daily living.Gerontologist1969;9:179-86

[24] Schwartz LH,de Vries E.RECIST 1.1-update and clarification: from the RECIST committee.Eur J Cancer2016;62:132-7 PMCID:PMC5737828

[25] Omarini C,Sperduti I.Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician?.BMC Cancer2020;20:418 PMCID:PMC7222291

[26] Caillet P,Brain E.PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: Baseline characteristics and safety evaluation.JCO2021;39:1012-1012

[27] Hu W,Jessen BA.Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies.Clin Cancer Res2016;22:2000-8

[28] Sammons SL,Blackwell KL.HR+, HER2- advanced breast cancer and CDK4/6 inhibitors: mode of action, clinical activity, and safety profiles.Curr Cancer Drug Targets2017;17:637-49 PMCID:PMC5652078

[29] Verma S,Schnell P.Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-Negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3).Oncologist2016;21:1165-75 PMCID:PMC5061543

[30] Clifton K,Kimmel J,Tripathy D.Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.Breast Cancer Res Treat2019;175:667-74 PMCID:PMC6535110

[31] DeMichele A,Brufsky A.Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.Breast Cancer Res2021;23:37 PMCID:PMC7989035

[32] Im SA,Bardia A.Overall survival with ribociclib plus endocrine therapy in breast cancer.N Engl J Med2019;381:307-16

[33] Hortobagyi GN,Burris HA.LBA17_PR - Overall Survival (OS) results from the Phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (Pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB).Ann Oncol2021;32:S1283-46

[34] O’Connor T,Doan C,Hurria A.Managing breast cancer in the older patient.Clin Adv Hematol Oncol2013;11:341-7 PMCID:PMC3906632

[35] Shruthi R,Pundarikaksha HP,Tushar TJ.A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital.J Clin Diagn Res2016;10:FC40-3 PMCID:PMC5296451

[36] Diéras V,Schnell P.Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer.J Natl Cancer Inst2019;111:419-30 PMCID:PMC6449170

[37] Varella L,Jia X.Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.Breast Cancer Res Treat2019;176:429-34

[38] Burstein HJ,Barton DL.Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update.J Clin Oncol2021;39:3959-77 PMCID:PMC8659999

[39] Gennari A,Barrios CH.Electronic address: [e-mail]. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.Ann Oncol2021;32:1475-95

[40] Biganzoli L,Wildiers H.Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).Lancet Oncol2021;22:e327-40

[41] Battisti NML,Sedrak MS.Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.Ther Adv Med Oncol2018;10:1758835918809610 PMCID:PMC6249663

[42] Puts MT,Fitch M.A systematic review of factors influencing older adults' decision to accept or decline cancer treatment.Cancer Treat Rev2015;41:197-215

[43] Wildiers H,Puts M.International society of geriatric oncology consensus on geriatric assessment in older patients with cancer.J Clin Oncol2014;32:2595-603 PMCID:PMC4876338

[44] Hjermstad M,Bjordal K.Using reference data on quality of life-the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3).Eur J Cancer1998;34:1381-9

[45] Wheelwright S,Fitzsimmons D.International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer.Br J Cancer2013;109:852-8 PMCID:PMC3749575